Protein expression profiles indicative for drug resistance of non-small cell lung cancer

被引:0
|
作者
M Volm
R Koomägi
J Mattern
T Efferth
机构
[1] German Cancer Research Centre,
[2] Virtual Campus Rhineland-Palatinate,undefined
来源
British Journal of Cancer | 2002年 / 87卷
关键词
non-small cell lung carcinomas; resistance factors; hierarchical cluster analysis;
D O I
暂无
中图分类号
学科分类号
摘要
Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising expression profiles may predict drug resistance with higher accuracy than single gene or protein expression studies. Forty cellular parameters (drug resistance proteins, proliferative, apoptotic, and angiogenic factors, products of proto-oncogenes, and suppressor genes) were evaluated mainly by immunohistochemistry in specimens of primary non-small cell lung carcinoma of 94 patients and compared with the response of the tumours to doxorubicin in vitro. The protein expression profile of non-small cell lung carcinoma was determined by hierarchical cluster analysis and clustered image mapping. The cluster analysis revealed three different resistance profiles. The frequency of each profile was different (77, 14 and 9%, respectively). In the most frequent drug resistance profile, the resistance proteins P-glycoprotein/MDR1 (MDR1, ABCB1), thymidylate-synthetase, glutathione-S-transferase-π, metallothionein, O6-methylguanine-DNA-methyltransferase and major vault protein/lung resistance-related protein were up-regulated. Microvessel density, the angiogenic factor vascular endothelial growth factor and its receptor FLT1, and ECGF1 as well were down-regulated. In addition, the proliferative factors proliferating cell nuclear antigen and cyclin A were reduced compared to the sensitive non-small cell lung carcinoma. In this resistance profile, FOS was up-regulated and NM23 down-regulated. In the second profile, only three resistance proteins were increased (glutathione-S-transferase-π, O6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). The angiogenic factors were reduced. In the third profile, only five of the resistance factors were increased (MDR1, thymidylate-synthetase, glutathione-S-transferase-π, O6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein).
引用
收藏
页码:251 / 257
页数:6
相关论文
共 50 条
  • [1] Protein expression profiles indicative for drug resistance of non-small cell lung cancer
    Volm, M
    Koomägi, R
    Mattern, J
    Efferth, T
    BRITISH JOURNAL OF CANCER, 2002, 87 (03) : 251 - +
  • [2] Drug resistance in non-small cell lung cancer
    Monzo, M
    Rosell, R
    Taron, M
    LUNG CANCER, 2001, 34 : S91 - S94
  • [3] MicroRNAs EXPRESSION PROFILES IN NON-SMALL CELL LUNG CANCER
    Yaroglu, Hatice Yildirim
    Akbayir, Serin
    Gorur, Aysegul
    Balci, Senay
    Unal, Nil
    Ayaz, Lokman
    Ayan, Erhan
    Tamer, Lulufer
    FRESENIUS ENVIRONMENTAL BULLETIN, 2021, 30 (7A): : 9107 - 9113
  • [4] Correlation of Specific MiRNAs Expression With Survival and Drug Resistance Related Protein Expression in Non-small Cell Lung Cancer
    Janikova, M.
    Zizkova, V.
    Skarda, J.
    Luzna, P.
    Radova, L.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S200 - S201
  • [5] MicroRNA Expression Profiles in Korean Non-Small Cell Lung Cancer
    Son, Ji Woong
    Kim, Young Jin
    Cho, Hyun Min
    Lee, Soo Young
    Jang, Jin Sung
    Choi, Jin Eun
    Lee, Jung Uee
    Kang, Min Gyu
    Lee, Yu Mi
    Kwon, Sun Jung
    Choi, Eugene
    Na, Moon Jun
    Park, Jae Yong
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 67 (05) : 413 - 421
  • [6] Restin protein expression in non-small cell lung cancer
    Nana, Frank Aboubakar
    Lamberts, Virginie
    Hoton, Delphine
    Stanciu, Claudia Pop
    Lecocq, Marylene
    Carlier, Francois M.
    Duplaquet, Fabrice
    Pirard, Lionel
    Pilette, Charles
    Bihin, Benoit
    Ocak, Sebahat
    THORACIC CANCER, 2023, 14 (23) : 2302 - 2309
  • [7] Reversible Drug Resistance Mechanisms in Non-small Cell Lung Cancer
    Haga, Yuya
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (12): : 1321 - 1326
  • [8] Salivary cytokine panel indicative of non-small cell lung cancer
    Koizumi, Tomonobu
    Shetty, Vivek
    Yamaguchi, Masaki
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (09) : 3570 - 3582
  • [9] Lung Resistance Protein and Multidrug Resistance Protein in Non-small Cell Lung Cancer and Their Clinical Significance
    Chen, Z. J.
    Le, H. B.
    Zhang, Y. K.
    Qian, L. Y.
    Sekhar, K. Raja
    Li, W. D.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (05) : 1693 - 1700
  • [10] Chemotherapy resistance and oncogene expression in non-small cell lung cancer
    d'Amato, Thomas A.
    Landreneau, Rodney J.
    Ricketts, William
    Huang, Weidong
    Parker, Ricardo
    Mechetner, Eugene
    Yu, Ing-Ru
    Luketich, James D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 133 (02): : 352 - 363